Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

Inclusion Criteria:

Stage 4 or unresectable stage 3 metastatic melanoma with or without measurable disease
Age 18-70 years old
Adequate pulmonary and cardiac function for high-dose IL-2
PS 0-2
Previous ipilimumab therapy will not exclude patients, but patients with previous ipilimumab will have separate efficacy analysis

Exclusion Criteria:

Brain metastases
Creatinine > 2x ULN; bilirubin > 3, WBC < 3500, Platelets < 100,000, Hgb < 9
Another active malignancy
Gastrointestinal tract metastases except rectal metastases or primary are allowable
Previous therapy for metastatic disease with chemotherapy of duration over 3 months or with high-dose interleukin-2
History of colitis or autoimmune disease such as lupus or rheumatoid arthritis
Bevacizumab-related contraindications: Hemoptysis or history of severe bleeding, uncontrolled hypertension, proteinuria with protein/creatinine ratio > 1, acute myocardial infarction within 6 months